Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials

2.

Hamid

O

,

Robert

C

,

Daud

A

,

Hodi

FS

,

Hwu

WJ

,

Kefford

R

, .

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

.

N Engl J Med

.

2013

;

369

:

134

–

44

.

3.

Melosky

B

,

Cheema

PK

,

Brade

A

,

McLeod

D

,

Liu

G

,

Price

PW

, .

Prolonging survival: the role of immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer

.

Oncologist

.

2020

;

25

:

981

–

92

.

4.

Topalian

SL

,

Hodi

FS

,

Brahmer

JR

,

Gettinger

SN

,

Smith

DC

,

McDermott

DF

, .

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

.

N Engl J Med

.

2012

;

366

:

2443

–

54

.

5.

Topalian

SL

,

Sznol

M

,

McDermott

DF

,

Kluger

HM

,

Carvajal

RD

,

Sharfman

WH

, .

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

.

J Clin Oncol

.

2014

;

32

:

1020

–

30

.

6.

Brahmer

J

,

Reckamp

KL

,

Baas

P

,

Crinò

L

,

Eberhardt

WE

,

Poddubskaya

E

, .

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

.

N Engl J Med

.

2015

;

373

:

123

–

35

.

7.

Fehrenbacher

L

,

Spira

A

,

Ballinger

M

,

Kowanetz

M

,

Vansteenkiste

J

,

Mazieres

J

, .

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

.

Lancet

.

2016

;

387

:

1837

–

46

.

8.

Herbst

RS

,

Garon

EB

,

Kim

DW

,

Cho

BC

,

Gervais

R

,

Perez-Gracia

JL

, .

Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed Death-Ligand 1-Positive advanced NSCLC

.

J Thorac Oncol

.

2021

;

16

(

10

):

1718

–

32

.

9.

Larkin

J

,

Minor

D

,

D’Angelo

S

,

Neyns

B

,

Smylie

M

,

Miller

WH

, .

Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-Label phase III trial

.

J Clin Oncol

.

2018

;

36

:

383

–

90

.

10.

Ma

VT

,

Daignault-Newton

S

,

Waninger

JJ

,

Journey

S

,

Chopra

Z

,

Tezel

A

, .

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma

.

Pigment Cell Melanoma Res

.

2021

;

34

(

3

):

629

–

40

.

11.

Ribas

A

,

Puzanov

I

,

Dummer

R

,

Schadendorf

D

,

Hamid

O

,

Robert

C

, .

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

.

Lancet Oncol

.

2015

;

16

:

908

–

18

.

12.

Robert

C

,

Long

GV

,

Brady

B

,

Dutriaux

C

,

Maio

M

,

Mortier

L

, .

Nivolumab in previously untreated melanoma without BRAF mutation

.

N Engl J Med

.

2015

;

372

:

320

–

30

.

13.

Weber

JS

,

Kähler

KC

,

Hauschild

A

.

Management of immune-related adverse events and kinetics of response with ipilimumab

.

J Clin Oncol

.

2012

;

30

:

2691

–

7

.

14.

Awad

MM

,

Gadgeel

SM

,

Borghaei

H

,

Patnaik

A

,

Yang

JC

,

Powell

SF

, .

Long-term overall survival from KEYNOTE-021 cohort g: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC

.

J Thorac Oncol

.

2021

;

16

(

1

):

162

–

8

.

15.

Garon

EB

,

Hellmann

MD

,

Rizvi

NA

,

Carcereny

E

,

Leighl

NB

,

Ahn

MJ

, .

Five-Year overall survival for patients with advanced Nonsmall-cell lung cancer treated with pembrolizumab: results from the phase i KEYNOTE-001 study

.

J Clin Oncol

.

2019

;

37

:

2518

–

27

.

16.

Garon

EB

,

Rizvi

NA

,

Hui

R

,

Leighl

N

,

Balmanoukian

AS

,

Eder

JP

, .

Pembrolizumab for the treatment of non-small-cell lung cancer

.

N Engl J Med

.

2015

;

372

:

2018

–

28

.

17.

Hui

R

,

Garon

EB

,

Goldman

JW

,

Leighl

NB

,

Hellmann

MD

,

Patnaik

A

, .

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

.

Ann Oncol

.

2017

;

28

:

874

–

81

.

18.

Langer

CJ

,

Gadgeel

SM

,

Borghaei

H

,

Papadimitrakopoulou

VA

,

Patnaik

A

,

Powell

SF

, .

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

.

Lancet Oncol

.

2016

;

17

:

1497

–

508

.

19.

Reck

M

,

Rodríguez-Abreu

D

,

Robinson

AG

,

Hui

R

,

Csőszi

T

,

Fülöp

A

, .

Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer

.

N Engl J Med

.

2016

;

375

:

1823

–

33

.

20.

Sul

J

,

Blumenthal

GM

,

Jiang

X

,

He

K

,

Keegan

P

,

Pazdur

R

.

FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed Death-Ligand 1

.

Oncologist

.

2016

;

21

:

643

–

50

.

21.

Mehra

R

,

Seiwert

TY

,

Gupta

S

,

Weiss

J

,

Gluck

I

,

Eder

JP

, .

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

.

Br J Cancer

.

2018

;

119

:

153

–

9

.

22.

Seiwert

TY

,

Burtness

B

,

Mehra

R

,

Weiss

J

,

Berger

R

,

Eder

JP

, .

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial

.

Lancet Oncol

.

2016

;

17

:

956

–

65

.

23.

Chen

R

,

Zinzani

PL

,

Fanale

MA

,

Armand

P

,

Johnson

NA

,

Brice

P

, .

Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma

.

J Clin Oncol

.

2017

;

35

:

2125

–

32

.

24.

Balar

AV

,

Galsky

MD

,

Rosenberg

JE

,

Powles

T

,

Petrylak

DP

,

Bellmunt

J

, .

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

.

Lancet

.

2017

;

389

:

67

–

76

.

25.

Bellmunt

J

,

de Wit

R

,

Vaughn

DJ

,

Fradet

Y

,

Lee

JL

,

Fong

L

, .

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

.

N Engl J Med

.

2017

;

376

:

1015

–

26

.

26.

Kobayashi

K

,

Suzuki

K

,

Hiraide

M

,

Aoyama

T

,

Yokokawa

T

,

Shikibu

S

, .

Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma

.

Oncology

.

2020

;

98

:

237

–

42

.

27.

Chao

J

,

Fuchs

CS

,

Shitara

K

,

Tabernero

J

,

Muro

K

,

Van Cutsem

E

, .

Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials

.

JAMA Oncol

.

2021

;

7

(

6

):

895

–

902

.

28.

Fuchs

CS

,

Doi

T

,

Jang

RW

,

Muro

K

,

Satoh

T

,

Machado

M

, .

Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial

.

JAMA Oncol

.

2018

;

4

:

e180013

.

29.

Postow

MA

,

Chesney

J

,

Pavlick

AC

,

Robert

C

,

Grossmann

K

,

McDermott

D

, .

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

.

N Engl J Med

.

2015

;

372

:

2006

–

17

.

30.

Weber

JS

,

D’Angelo

SP

,

Minor

D

,

Hodi

FS

,

Gutzmer

R

,

Neyns

B

, .

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

.

Lancet Oncol

.

2015

;

16

:

375

–

84

.

31.

Motzer

RJ

,

Escudier

B

,

George

S

,

Hammers

HJ

,

Srinivas

S

,

Tykodi

SS

, .

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

.

Cancer

.

2020

;

126

:

4156

–

67

.

32.

Motzer

RJ

,

Escudier

B

,

McDermott

DF

,

George

S

,

Hammers

HJ

,

Srinivas

S

, .

Nivolumab versus everolimus in advanced renal-cell carcinoma

.

N Engl J Med

.

2015

;

373

:

1803

–

13

.

33.

Ansell

SM

.

Nivolumab in the treatment of hodgkin lymphoma

.

Clin Cancer Res

.

2017

;

23

(

7

):

1623

–

6

.

34.

Ansell

SM

,

Lesokhin

AM

,

Borrello

I

,

Halwani

A

,

Scott

EC

,

Gutierrez

M

, .

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma

.

N Engl J Med

.

2015

;

372

:

311

–

9

.

35.

Younes

A

,

Santoro

A

,

Shipp

M

,

Zinzani

PL

,

Timmerman

JM

,

Ansell

S

, .

Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

.

Lancet Oncol

.

2016

;

17

:

1283

–

94

.

36.

Galsky

MD

,

Saci

A

,

Szabo

PM

,

Han

GC

,

Grossfeld

G

,

Collette

S

, .

Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275

.

Clin Cancer Res

.

2020

;

26

:

5120

–

8

.

37.

Sharma

P

,

Retz

M

,

Siefker-Radtke

A

,

Baron

A

,

Necchi

A

,

Bedke

J

, .

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

.

Lancet Oncol

.

2017

;

18

:

312

–

22

.

38.

Morse

MA

,

Overman

MJ

,

Hartman

L

,

Khoukaz

T

,

Brutcher

E

,

Lenz

HJ

, .

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

.

Oncologist

.

2019

;

24

:

1453

–

61

.

39.

Overman

MJ

,

McDermott

R

,

Leach

JL

,

Lonardi

S

,

Lenz

HJ

,

Morse

MA

, .

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

.

Lancet Oncol

.

2017

;

18

:

1182

–

91

.

40.

El-Khoueiry

AB

,

Sangro

B

,

Yau

T

,

Crocenzi

TS

,

Kudo

M

,

Hsu

C

, .

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

.

Lancet

.

2017

;

389

:

2492

–

502

.

41.

Julien

K

,

Leung

HT

,

Fuertes

C

,

Mori

M

,

Wang

MJ

,

Teo

J

, .

Nivolumab in advanced hepatocellular carcinoma: safety profile and select Treatment-Related adverse events from the CheckMate 040 study

.

Oncologist

.

2020

;

25

(

10

):

e1532

–

40

.

42.

Rosenberg

JE

,

Hoffman-Censits

J

,

Powles

T

,

van der Heijden

MS

,

Balar

AV

,

Necchi

A

, .

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

.

Lancet

.

2016

;

387

:

1909

–

20

.

43.

Rittmeyer

A

,

Barlesi

F

,

Waterkamp

D

,

Park

K

,

Ciardiello

F

,

von Pawel

J

, .

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

.

Lancet

.

2017

;

389

:

255

–

65

.

44.

von Pawel

J

,

Bordoni

R

,

Satouchi

M

,

Fehrenbacher

L

,

Cobo

M

,

Han

JY

, .

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study

.

Eur J Cancer

.

2019

;

107

:

124

–

32

.

45.

Apolo

AB

,

Infante

JR

,

Balmanoukian

A

,

Patel

MR

,

Wang

D

,

Kelly

K

, .

Avelumab, an anti-programmed Death-Ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study

.

J Clin Oncol

.

2017

;

35

:

2117

–

24

.

46.

Massard

C

,

Gordon

MS

,

Sharma

S

,

Rafii

S

,

Wainberg

ZA

,

Luke

J

, .

Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

.

J Clin Oncol

.

2016

;

34

:

3119

–

25

.

47.

Rotman

J

,

Mom

CH

,

Jordanova

ES

,

de Gruijl

TD

,

Kenter

GG

,

‘Durvit’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer – safety, toxicity and effect on the primary tumour- and lymph node microenvironment

.

BMC Cancer

.

2018

;

18

:

888

.

48.

Michot

JM

,

Bigenwald

C

,

Champiat

S

,

Collins

M

,

Carbonnel

F

,

Postel-Vinay

S

, .

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

.

Eur J Cancer

.

2016

;

54

:

139

–

48

.

49.

Som

A

,

Mandaliya

R

,

Alsaadi

D

,

Farshidpour

M

,

Charabaty

A

,

Malhotra

N

, .

Immune checkpoint inhibitor-induced colitis: a comprehensive review

.

WORLD J Clin Cases

.

2019

;

7

:

405

–

18

.

50.

Tirumani

SH

,

Ramaiya

NH

,

Keraliya

A

,

Bailey

ND

,

Ott

PA

,

Hodi

FS

, .

Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab

.

Cancer Immunol Res

.

2015

;

3

:

1185

–

92

.

51.

Champiat

S

,

Lambotte

O

,

Barreau

E

,

Belkhir

R

,

Berdelou

A

,

Carbonnel

F

, .

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

.

Ann Oncol

.

2016

;

27

:

559

–

74

.

52.

Gettinger

SN

,

Horn

L

,

Gandhi

L

,

Spigel

DR

,

Antonia

SJ

,

Rizvi

NA

, .

Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer

.

J Clin Oncol

.

2015

;

33

:

2004

–

12

.

53.

Nishino

M

,

Giobbie-Hurder

A

,

Hatabu

H

,

Ramaiya

NH

,

Hodi

FS

.

Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis

.

JAMA Oncol

.

2016

;

2

:

1607

–

16

.

54.

Jadad

AR

,

Moore

RA

,

Carroll

D

,

Jenkinson

C

,

Reynolds

DJ

,

Gavaghan

DJ

, .

Assessing the quality of reports of randomized clinical trials: is blinding necessary

.

Control Clin Trials

.

1996

;

17

:

1

–

12

.

55.

Antonia

SJ

,

Villegas

A

,

Daniel

D

,

Vicente

D

,

Murakami

S

,

Hui

R

, .

Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer

.

N Engl J Med

.

2017

;

377

:

1919

–

29

.

56.

Eggermont

AMM

,

Blank

CU

,

Mandala

M

,

Long

GV

,

Atkinson

V

,

Dalle

S

, .

Adjuvant pembrolizumab versus placebo in resected stage III Melanoma

.

N Engl J Med

.

2018

;

378

:

1789

–

801

.

57.

Gandhi

L

,

Rodríguez-Abreu

D

,

Gadgeel

S

,

Esteban

E

,

Felip

E

,

De Angelis

F

, .

Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer

.

N Engl J Med

.

2018

;

378

:

2078

–

92

.

58.

Socinski

MA

,

Jotte

RM

,

Cappuzzo

F

,

Orlandi

F

,

Stroyakovskiy

D

,

Nogami

N

, .

Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

.

N Engl J Med

.

2018

;

378

:

2288

–

301

.

59.

Hamid

O

,

Puzanov

I

,

Dummer

R

,

Schachter

J

,

Daud

A

,

Schadendorf

D

, .

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

.

Eur J Cancer

.

2017

;

86

:

37

–

45

.

60.

Herbst

RS

,

Baas

P

,

Kim

DW

,

Felip

E

,

Pérez-Gracia

JL

,

Han

JY

, .

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

.

Lancet

.

2016

;

387

:

1540

–

50

.

61.

Carbone

DP

,

Reck

M

,

Paz-Ares

L

,

Creelan

B

,

Horn

L

,

Steins

M

, .

First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

.

N Engl J Med

.

2017

;

376

:

2415

–

26

.

62.

Larkin

J

,

Chiarion-Sileni

V

,

Gonzalez

R

,

Grob

JJ

,

Rutkowski

P

,

Lao

CD

, .

Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

.

N Engl J Med

.

2019

;

381

:

1535

–

46

.

63.

Robert

C

,

Schachter

J

,

Long

GV

,

Arance

A

,

Grob

JJ

,

Mortier

L

, .

Pembrolizumab versus ipilimumab in advanced melanoma

.

N Engl J Med

.

2015

;

372

:

2521

–

32

.

64.

Wolchok

JD

,

Chiarion-Sileni

V

,

Gonzalez

R

,

Rutkowski

P

,

Grob

JJ

,

Cowey

CL

, .

Overall survival with combined nivolumab and ipilimumab in advanced melanoma

.

N Engl J Med

.

2017

;

377

:

1345

–

56

.

65.

Antonia

SJ

,

López-Martin

JA

,

Bendell

J

,

Ott

PA

,

Taylor

M

,

Eder

JP

, .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

.

Lancet Oncol

.

2016

;

17

:

883

–

95

.

66.

Long

GV

,

Atkinson

V

,

Lo

S

,

Sandhu

S

,

Guminski

AD

,

Brown

MP

, .

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

.

Lancet Oncol

.

2018

;

19

:

672

–

81

.

67.

Motzer

RJ

,

Rini

BI

,

McDermott

DF

,

Redman

BG

,

Kuzel

TM

,

Harrison

MR

, .

Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial

.

J Clin Oncol

.

2015

;

33

:

1430

–

7

.

68.

Ferris

RL

,

Blumenschein

G

,

Fayette

J

,

Guigay

J

,

Colevas

AD

,

Licitra

L

, .

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

.

Oral Oncol

.

2018

;

81

:

45

–

51

.

69.

Robert

C

,

Ribas

A

,

Wolchok

JD

,

Hodi

FS

,

Hamid

O

,

Kefford

R

, .

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

.

Lancet

.

2014

;

384

:

1109

–

17

.

70.

Atkins

MB

,

Hodi

FS

,

Thompson

JA

,

McDermott

DF

,

Hwu

WJ

,

Lawrence

DP

, .

Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 Study

.

Clin Cancer Res

.

2018

;

24

:

1805

–

15

.

71.

Weber

JS

,

Gibney

G

,

Sullivan

RJ

,

Sosman

JA

,

Slingluff

CL

,

Lawrence

DP

, .

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

.

Lancet Oncol

.

2016

;

17

:

943

–

55

.

72.

Maio

M

,

Scherpereel

A

,

Calabrò

L

,

Aerts

J

,

Perez

SC

,

Bearz

A

, .

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

.

Lancet Oncol

.

2017

;

18

:

1261

–

73

.

73.

Bouros

D

,

Hatzakis

K

,

Labrakis

H

,

Zeibecoglou

K

.

Association of malignancy with diseases causing interstitial pulmonary changes

.

Chest

.

2002

;

121

:

1278

–

89

.

74.

Coussens

LM

,

Werb

Z

.

Inflammation and cancer

.

Nature

.

2002

;

420

:

860

–

7

.

75.

Tan

TT

,

Coussens

LM

.

Humoral immunity, inflammation and cancer

.

Curr Opin Immunol

.

2007

;

19

:

209

–

16

.

76.

Toh

CK

,

Wong

EH

,

Lim

WT

,

Leong

SS

,

Fong

KW

,

Wee

J

, .

The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis

.

Chest

.

2004

;

126

:

1750

–

6

.

77.

Khunger

M

,

Rakshit

S

,

Pasupuleti

V

,

Hernandez

AV

,

Mazzone

P

,

Stevenson

J

, .

Incidence of pneumonitis with use of programmed death 1 and programmed Death-Ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials

.

Chest

.

2017

;

152

:

271

–

81

.